Hepatitis C

Liver and Treatment Failure Cases Linked With Newer HCV Antivirals

Liver and Treatment Failure Cases Linked With Newer HCV Antivirals

By

While direct-acting antivirals represent an important advance in the treatment of hepatitis C virus infection, further investigation is needed to understand the reasons for the cases of liver failure and antiviral failure reported to the FDA.

HCV Infection Linked to Nonhepatic Cancers in the Elderly

HCV Infection Linked to Nonhepatic Cancers in the Elderly

By

In the elderly population, hepatitis C virus infection is associated with cancers other than hepatocellular carcinoma, such as bile duct and pancreatic cancers and diffuse large B-cell lymphoma.

Neuropsychiatric Impairment in Patients With HCV Despite Virus Clearance

Neuropsychiatric Impairment in Patients With HCV Despite Virus Clearance

By

Neuropsychiatric syndrome not linked to virus in hepatitis C infection.

Targeted CBT for HCV Patients Helps to Reduce Pain and Substance Use

Targeted CBT for HCV Patients Helps to Reduce Pain and Substance Use

By

Customized CBT reduced substance use disorder, pain severity, and pain interference in veterans with HCV.

FDA Grants Priority Review to Fixed-Dose Pan-Genotypic HCV Regimen

FDA Grants Priority Review to Fixed-Dose Pan-Genotypic HCV Regimen

By

Priority Review granted to the NDA of glecaprevir/pibrentasvir (G/P; AbbVie) for the treatment of genotypes 1-6 chronic hepatitis C virus infection.

Telemedicine Improves Hepatitis C Treatment Rates in Rural Areas

Telemedicine Improves Hepatitis C Treatment Rates in Rural Areas

By

Using telemedicine consults with specialists to support PCPs enhanced the treatment rates in hepatitis C in rural areas.

Reducing Diabetes Risk Key to Eradicating HCV in Coinfected Patients

Reducing Diabetes Risk Key to Eradicating HCV in Coinfected Patients

Sustained viral response correlated with a significant decrease in the risk of diabetes mellitus and a trend towards decrease in chronic renal failure, according to a study.

Short-Duration Triple DAA for Chronic HCV With Portal Hypertension

Short-Duration Triple DAA for Chronic HCV With Portal Hypertension

By

Trial finds the combination of simeprevir, daclatasvir, and sofosbuvir generally safe and well tolerated in HCV patients with decompensated liver disease.

Multiple Updates for Atazanavir and Cobicistat HIV Combination Tx

Multiple Updates for Atazanavir and Cobicistat HIV Combination Tx

By

Evotaz label has been updated to include data from Trial 114 including updates to the drug interactions and specific populations sections.

Effectiveness of Sorafenib Dependent on Hepatitis Status in HCC

Effectiveness of Sorafenib Dependent on Hepatitis Status in HCC

Meta-analysis shows consistent evidence that in advanced unresectable hepatocellular carcinoma, the effect of sorafenib on overall survival is dependent on patients' hepatitis status.

ART Improves Liver Fibrosis in Majority of Patients With HIV

ART Improves Liver Fibrosis in Majority of Patients With HIV

By

Combination antiretroviral therapy is associated with an overall reduction in liver fibrosis in HIV-infected patients with and without hepatitis co-infections.

Liver- and Non-Liver Related Critical Events Down in HCV and Cirrhosis

Liver- and Non-Liver Related Critical Events Down in HCV and Cirrhosis

Researchers found that 50.5% of the patients achieved sustained viral response, which correlated with reduced incidence of hepatocellular carcinoma and hepatic decompensation.

Shorter Ledipasvir/Sofosbuvir Treatment Highly Effective in HCV GT1

Shorter Ledipasvir/Sofosbuvir Treatment Highly Effective in HCV GT1

By

The 8-week regimen of LDV/SOF for HCV genotype 1 induced sustained virologic response at 12 weeks in nearly all patients treated.

HCV Antivirals Produce Durable Responses Despite Time to Suppression

HCV Antivirals Produce Durable Responses Despite Time to Suppression

By

Newer combinations of HCV genotype 1b antivirals showed sustained virologic response independent of time to viral suppression.

Ledipasvir-Sofosbuvir Effective in Treating Adolescents With HCV GT1

Ledipasvir-Sofosbuvir Effective in Treating Adolescents With HCV GT1

Phase 2 multi-center study examined the efficacy and safety of ledipasvir-sofosbuvir in 100 adolescents with chronic HCV genotype 1 infection.

Abbvie Submits New Drug Application to FDA for All Major HCV Genotypes

Abbvie Submits New Drug Application to FDA for All Major HCV Genotypes

By

NDA submitted to the FDA by AbbVie for its investigational regimen of glecaprevir/pibrentasvir to treat all major genotypes of chronic HCV.

Diabetes Increases Risk of Hepatocellular Carcinoma in HCV Patients

Diabetes Increases Risk of Hepatocellular Carcinoma in HCV Patients

Diabetes increased the risk of hepatocellular carcinoma development and all-cause mortality in patients infected with HCV.

WHO Prequalifies First HCV Rapid Diagnostic Test

WHO Prequalifies First HCV Rapid Diagnostic Test

By

The World Health Organization has just prequalified its first hepatitis C virus point-of-care diagnostic test.

FDA: Review Underway for Single Tablet HCV Regimen

FDA: Review Underway for Single Tablet HCV Regimen

By

The once-daily single tablet regimen of sofosbuvir/velpatasvir/voxilaprevir is intended for patients with direct-acting antiviral-experienced hepatitis C infections.

Ledipasvir-sofosbuvir Ok'd for Kidney Recipients With HCV

Ledipasvir-sofosbuvir Ok'd for Kidney Recipients With HCV

Safety and efficacy was shown in kidney transplant recipients with hepatitis C virus genotype 1 or 4 infection.

HCV Treatment Before Liver Transplant Increases Life Expectancy

HCV Treatment Before Liver Transplant Increases Life Expectancy

HCV treatment before liver transplant increased life expectancy if model for end-stage liver disease was ≤ 27.

Low Incidence of Late Recurrent Viremia With Ledipasvir/Sofosbuvir

Low Incidence of Late Recurrent Viremia With Ledipasvir/Sofosbuvir

By

Researchers evaluated the prevalence of late recurrent viremia following sofosbuvir-based treatment.

Possible Interaction Between HCV Treatment Identified

Possible Interaction Between HCV Treatment Identified

Probable interaction between paritaprevir/ritonavir/ombitasvir+dasabuvir (PrOD) plus ribavirin with warfarin identified in a case report.

WHO: New Hepatitis C Drugs Reaches More Than 1 Million People

WHO: New Hepatitis C Drugs Reaches More Than 1 Million People

High prices have been a barrier to HCV treatment but WHO reports that prices in low- and certain middle-income countries are declining.

ID Specialist Involvement Key to Successfully Treating Hepatitis C

ID Specialist Involvement Key to Successfully Treating Hepatitis C

By

ID specialists need to take a major role in the implementation of new treatments for HCV.

Hepatitis C Treatment Impacted by Pharmacist Integration in Care Team

Hepatitis C Treatment Impacted by Pharmacist Integration in Care Team

By

Researchers found that an innovative hepatitis C care program had positive outcomes after the integration of pharmacists onto the care team.

Global Burden of Hepatitis, HIV Linked to Injection Drug Use

Global Burden of Hepatitis, HIV Linked to Injection Drug Use

By

The rate of global disease burden of HIV, HCV, and HBV in injection drug users has nearly quadrupled between 1990 and 2013.

Fibrosis Progression in Patients With HCV Not Linear

Fibrosis Progression in Patients With HCV Not Linear

By

Fibrosis progression in patients with hepatitis C virus varies according to stage.

VA Expands Treatment to All Veterans With Hep C

VA Expands Treatment to All Veterans With Hep C

By

Offering treatment to all veterans puts the VA at the forefront of combating hepatitis C.

IDSA, AASLD Update Hepatitis Guidance

IDSA, AASLD Update Hepatitis Guidance

The update also offers guidance regarding the prudent use of HCV resistance testing, a source of considerable confusion for practitioners.

Sign Up for Free e-newsletters